Review on chemogenomic approaches towards hepatitis C viral targets.

Hepatitis C virus (HCV) is the most prevalent viral pathogen that infects more than 185 million people worldwide. HCV infection leads to chronic liver diseases such as liver cirrhosis and hepatocellular carcinoma. Direct-acting antivirals (DAAs) are the recent combination therapy for HCV infection with reduced side effects than prior therapies. Sustained virological response (SVR) acts as a gold standard marker to monitor the success of antiviral treatment. Older treatment therapies attain 50-55% of SVR compared with DAAs which attain around 90-95%. The current review emphasizes the recent chemogenomic updates that have been unfolded through structure-based drug design of HCV drug target proteins (NS3/4A, NS5A, and NS5B) and ligand-based drug design of DAAs in achieving a stable HCV viral treatment strategies.

Activation mechanism of claudin-4 by ephrin type-A receptor 2: a molecular dynamics approach.

Claudin-4 is a crucial component in the tight junction which is involved in the organization of a cellular barrier. Claudin-4 is found to be up-regulated in various malignancies and is activated by forming a complex with an ephrin A2 receptor. In this computational study, we propose a rational model for the claudin-4-ephrinA2 complex which is in agreement with the experimental result. The complex model has been obtained through protein-protein docking, interface residue scanning, in silico alanine mutations and extensive molecular dynamics simulations. The docking model envisages the important residues present in the first extracellular loop of claudin-4 that plays an active role in protein-protein interaction and stability. A 30 nanosecond molecular dynamics simulation of the complex revealed a higher stability by which the number of hydrogen bond interactions increased in the complex interface. Both the molecular dynamics simulations and in silico alanine mutations revealed the involvement of Lys65 (claudin-4) as one of the prime residues in the complex interface that is actively engaged in the binding mechanism with its counterpart. We postulate that the novel hotspot, Lys65 of claudin-4 can be targeted through structure based inhibitor design, which could alter the effect of the claudin-4-ephrinA2 binding mechanism in aggressive metastatic tumors.